• Cytoprotective and supportive care agents

Voraxaze Generic Name & Formulations

General Description

Glucarpidase; 1,000 Units/vial; lyophilized pwd for IV inj after reconstitution; preservative-free.

Pharmacological Class

Carboxypeptidase enzyme.

How Supplied

Single-dose vials—1


Generic Availability


Voraxaze Indications


Treatment of toxic plasma methotrexate (MTX) concentrations (>1 micromole per liter) in patients with delayed MTX clearance due to impaired renal function.

Limitations of Use

Not recommended in those who exhibit the expected clearance and expected plasma methotrexate concentration; may result in subtherapeutic exposure.

Voraxaze Dosage and Administration

Adults and Children

<1 month: not established. ≥1 month: Give as bolus IV inj over 5mins. 50Units/kg as a single injection. First 48hrs after glucarpidase: administer same leucovorin dose as given prior to glucarpidase. Beyond 48hrs after glucarpidase: determine leucovorin dose based on the measured MTX concentration. Continue leucovorin until the MTX concentration has been maintained below the leucovorin rescue threshold for a minimum of 3 days.

Voraxaze Contraindications

Not Applicable

Voraxaze Boxed Warnings

Not Applicable

Voraxaze Warnings/Precautions


Monitor MTX concentrations only by chromatographic methods within 48hrs following administration. Continue hydration and alkalinization of urine as indicated. Pregnancy. Nursing mothers.

Voraxaze Pharmacokinetics

See Literature

Voraxaze Interactions


May reduce concentrations of leucovorin, other folate analogs or folate analog metabolic inhibitors. When concomitant leucovorin, give at least 2hrs before or 2hrs after glucarpidase administration.

Voraxaze Adverse Reactions

Adverse Reactions

Paresthesia, flushing, nausea, vomiting, hypotension, headache; rare: hypersensitivity reactions, antibody formation.

Voraxaze Clinical Trials

See Literature

Voraxaze Note

Not Applicable

Voraxaze Patient Counseling

See Literature